Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity (2016 - 2025)

Cumberland Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $76.8 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 1.64% year-over-year to $76.8 million; the TTM value through Dec 2025 reached $280.6 million, down 10.18%, while the annual FY2025 figure was $76.8 million, 1.64% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $76.8 million at Cumberland Pharmaceuticals, up from $65.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $96.7 million in Q1 2022 and bottomed at $65.9 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $87.6 million (2021), against an average of $83.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity rose 10.02% in 2022 before it decreased 14.2% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $84.5 million in 2021, then grew by 10.02% to $92.9 million in 2022, then decreased by 5.57% to $87.8 million in 2023, then fell by 13.87% to $75.6 million in 2024, then increased by 1.64% to $76.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Liabilities and Shareholders Equity are $76.8 million (Q4 2025), $65.9 million (Q3 2025), and $67.9 million (Q2 2025).